|
⚲
|
| Keyboard |
| Rock Springs Capital Management LP
✚
|
|
|---|---|
| CRD # | 168648 |
| SEC # | 801-78511 |
| CIK # | 0001595725, 0001735397 |
| AUM | 2,426.3 M (2026-03-24) |
| Employees | 17 (47% Investors, 0% Brokers) |
| Phone | 410-220-0130 |
| Address | 650 S Exeter Street Baltimore, MD 21202 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Revolution Medicines Inc | 0.1 | ||
| Lilly Eli & Co | 0.1 | ||
| Synta Pharmaceuticals Corp | 0.1 | ||
| Mirum Pharmaceuticals Inc | 0.1 | ||
| Argenx SE | 0.1 | ||
| Rhythm Pharmaceuticals Inc | 0.1 | ||
| Insmed Inc | 0.1 | ||
| Ascendis Pharma A/S | 0.0 | ||
| Xenon Pharmaceuticals Inc | 0.0 | ||
| Desert Gateway Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Four Pines Master Fund LP | [2020-03-30] | 186.0 M | 311.1 M |
| Filed 2026-03-20 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Rock Springs Capital Master Fund LP | [2014-01-22] | 2,472.6 M | 2,115.2 M |
| Filed 2026-01-21 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 6 | 2.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 6 | 2.4 |
| By Discretionary | ||
| Discretionary | 6 | 2.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 6 | 2.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.6 | |
| United States Persons | 1.9 | |
| Total | 6 | 2.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Kris Jenner | Executive Officer | 7 | 2 | |
| Gordon Bussard | Executive Officer | 4 | 2 | |
| Graham McPhail | Executive Officer | 4 | 2 | |
| Rock Springs Capital Management LP | Executive Officer | 4 | 2 | |
| Rock Springs General Partner LLC | Executive Officer | 2 | 2 | |
| Four Pines General Partner LLC | Executive Officer | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001595725] | |
| 3 | [0001595725] | |
| 4 | [0001595725] | |
| SC 13G | [0001595725] | |
| 3 | [0001735397] | |
| 4 | [0001735397] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.3B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 5493004NKG0T3VM7NZ08 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Conversion | 756,472 | ||
|
Xilio Therapeutics Inc XLO
Series C Preferred Stock · derivative
|
2021-10-26 | Conversion | 7,186,490 | ||
|
Xilio Therapeutics Inc XLO
Series C Preferred Stock · derivative
|
2021-10-26 | Conversion | 1,437,297 | ||
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Buy | 500,000 | $16.00 | 8,000,000 |
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Conversion | 151,294 | ||
|
Theseus Pharmaceuticals Inc THRX
Series B Convertible Preferred Stock · derivative
|
2021-10-12 | Conversion | 349,320 | ||
|
Theseus Pharmaceuticals Inc THRX
Common Stock
|
2021-10-12 | Buy | 250,000 | $16.00 | 4,000,000 |
|
Theseus Pharmaceuticals Inc THRX
Common Stock
|
2021-10-12 | Conversion | 87,329 | ||
|
Theseus Pharmaceuticals Inc THRX
Common Stock
|
2021-10-12 | Conversion | 349,320 | ||
|
Theseus Pharmaceuticals Inc THRX
Series B Convertible Preferred Stock · derivative
|
2021-10-12 | Conversion | 87,329 | ||
|
Verve Therapeutics Inc VERV
Common Stock
|
2021-06-21 | Conversion | 556,298 | ||
|
Verve Therapeutics Inc VERV
Common Stock
|
2021-06-21 | Buy | 370,000 | $19.00 | 7,030,000 |
|
Verve Therapeutics Inc VERV
Common Stock
|
2021-06-21 | Conversion | 152,926 | ||
|
Verve Therapeutics Inc VERV
Series B Preferred Stock · derivative
|
2021-06-21 | Conversion | 1,416,023 | ||
|
Verve Therapeutics Inc VERV
Series B Preferred Stock · derivative
|
2021-06-21 | Conversion | 5,151,043 | ||
|
Atea Pharmaceuticals Inc AVIR
Series D Convertible Preferred Stock · derivative
|
2020-11-03 | Conversion | 178,063 | ||
|
Atea Pharmaceuticals Inc AVIR
Series D-1 Convertible Preferred Stock · derivative
|
2020-11-03 | Conversion | 104,340 | ||
|
Atea Pharmaceuticals Inc AVIR
Series D Convertible Preferred Stock · derivative
|
2020-11-03 | Conversion | 890,313 | ||
|
Atea Pharmaceuticals Inc AVIR
Common Stock
|
2020-11-03 | Buy | 7,292 | $24.00 | 175,008 |
|
Atea Pharmaceuticals Inc AVIR
Common Stock
|
2020-11-03 | Buy | 242,708 | $24.00 | 5,824,992 |
| showing 20 of 38 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Analog Century Management LP
✚
|
NY | 2,451.6 M |
|
683 Capital Management LLC
✚
|
NY | 2,436.9 M |
|
Long Focus Capital Management LLC
✚
|
PR | 2,436.5 M |
|
Permian Investment Partners LP
✚
|
TX | 2,433.6 M |
|
Dark Forest Capital Management LP
✚
|
NY | 2,417.0 M |
|
CoreCommodity Management LLC
✚
|
CT | 2,413.9 M |
|
Forest Avenue Capital Management LP
✚
|
FL | 2,406.0 M |
|
Kynam Capital Management LP
✚
|
2,405.4 M | |
|
Alatus Capital LLC
✚
|
2,398.4 M | |
|
Heard Capital LLC
✚
|
IL | 2,395.9 M |